Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension

Exclusion Criteria

• •Any significant clinical condition that, in the investigator's opinion, may interfere with participant safety;
• •Any laboratory test finding that, in the investigator's opinion, may interfere with participant safety;
• •Suspected or diagnosed with COVID 19;
• •History of hypersensitivity to components of drugs used during the trial or to drugs derived from sulfonamides;
• •Pregnant or breastfeeding women;
• •Women in a reproductive age who do not agree to use contraceptive methods;
• •Male participants who do not agree to use contraceptive methods;
• •Participation in clinical trial protocols in the last 12 (twelve) months, unless the investigator judges that there may be a direct benefit to the participant;
• •Participant who has some kind of relationship up to the second degree or bond with collaborators or employees of the Sponsor and the Research site;
• •Estimated glomerular filtration rate (eGFR) less than 45 ml/min /1.73m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation) or end-stage renal disease;
• •Severe liver dysfunction;
• •Cardiogenic shock or reduced ejection fraction heart failure with a left ventricular ejection fraction less than or equal to 50%;
• •Symptomatic congestive heart failure class II, III or IV, according to the New York Heart Association and/or participants with a history of infarction, unstable angina or cerebrovascular accident in the last 6 months prior to the beginning of the study;
• •Clinically relevant ventricular cardiac arrhythmias;
• •Obstructive coronary artery disease planning percutaneous or surgical intervention;
• •Dementia syndrome;
• •History of alcohol or illicit drug addiction in the six months prior to the date of signature of the Informed Consent Form;
• •Obstructive biliary disorders;
• •Refractory hypokalemia and/or conditions involving marked potassium loss, hyperkalemia (\>5,5 mmol/L), and/or hyponatremia;
• •History of symptomatic hyperuricemia;
• •History of secondary hypertension;
• •History of cancer, without documentation of remission/cure;